Downloads
Abstract
Objectives: Lung cancer is the leading cause of cancer death around the world. Systemic therapy plays a key role in the treatment of metastatic non - small cell lung cancer patients. Tyrosine kinase inhibitors are indicated in the first- line treatment for EGFR mutation metastatic non - small cell lung cancer patients. Analyzing survival outcomes and some influent factors of first - line erlotinib treatment in EGFR mutation metastatic non - small cell lung cancer patients at Nghe An Oncology Hospital.
Methods: Retrospective and prospective analysis of 74 EGFR mutation metastatic non-small cell lung cancer patients were diagnosed and treated with first - line erlotinib at Nghe An Oncology Hospital from January 2017 to May 31, 2023.
Results: The mean progression - free survival (PFS) time was 15.5 ± 1.2 months, the PFS rate at 1 year was 44.6%. The mean overall survival (OS) time was 27.2 ± 2.4 months, the OS rates at 1 year and 2 years were 73.4% and 47.4%, respectively. The number of metastatic organs, brain metastases with or without brain radiation, skin rash, and response to treatment are factors related to progression - free survival time. Overall survival was related to sex, smoking status, brain metastases with or without brain radiation, skin rash, disease response and second - line regimen. Multivariate analysis showed treatment response was independently related to progression - free survival, and factors such as age, smoking status, brain metastases, and disease response were independently related to overall survival.
Conclusions: Treatment first - line erlotinib gave positive survival results in EGFR mutation metastatic non - small cell lung cancer patients. Treatment response was independently associated with progression - free survival. Overall survival was independently associated with age, smoking status, brain metastases, and disease response.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2021; 71(3): 209-249.
Bộ Y tế. Hướng dẫn chẩn đoán và điều trị một số bệnh ung bướu. 2020: 867-892.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8): 735-42.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3
trial. Lancet Oncol. 2012; 13(3): 239-46.
Paz-Ares L, Soulieres D, Moecks J, Bara I, Mok T, Klughammer B. Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC. J Cell Mol Med. 2014; 18(8): 1519-39.
Hà NM, Khánh TV, Văn TT, CS. Erlotinib bước một trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn muộn có đột biến gen EGFR. Tạp chí nghiên cứu y học. 2014: Phụ trương 91, 7-14.
Hà LT, Đánh giá hiệu quả thuốc erlotinib trong điều trị ung thư phổi biểu mô tuyến giai đoạn muộn. 2017, Trường Đại học Y Hà Nội: Luận án Tiến sỹ Y học.
Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, et al. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016; 34(27): 3248-57.
Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small- cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015; 26(9): 1883-1889.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol.
; 26(9): 1877-1883.
Kainis I, Syrigos N, Kopitopoulou A, Gkiozos I, Filiou E, Nikolaou V, et al. Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival. Oncol Res. 2018; 26(1): 59-69.
| Published | 26-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 91 (2023) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.91.4 | |
| Keywords | Ung thư phổi không tế bào nhỏ, đột biến EGFR, erlotinib, TKIs Non - small cell lung cancer, EGFR mutation, erlotinib, tyrosine kinase inhibitors |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Clinical Medicine Hue Central Hospital